FINAL REPORT

Patient:
Sex:
DOB:
Client:
Provider:

Specimen ID:
Sample location:
Collected:
Received:
Reported:

GEP Result

JAK Inhibitor Responder Profile

Gene expression profile is associated with a significantly higher clinical benefit from JAK inhibitor therapy.

Clinical Interpretation

Patients with a JAK inhibitor responder profile are more likely to achieve optimal outcomes when treated with a JAK inhibitor compared to a Th2-targeted therapy:

- **Higher rates of overall disease improvement and near clear skin (EASI-90, vIGA-AD 0, or BSA 0) by 3 months**
- **Reduction in itch severity**
- **Improved quality of life (DLQI 0)**
- **Fewer disease flares**
- **Faster time to achieve disease improvement (EASI-90)**

The AdvanceAD-Tx test is intended to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis.

Castle Biosciences, Inc. | Sherri Borman, PhD, HCLD, Lab Director

FINAL REPORT

Patient:
Sex:
DOB:
Client:
Provider:

Specimen ID:
Sample location:
Collected:
Received:
Reported:

GEP Result

Th2 Molecular Profile

Gene expression profile is associated with similar clinical benefit regardless of treatment with a Th2-targeted or JAK inhibitor therapy.

Clinical Interpretation

Patients with a Th2 molecular profile show no statistical difference in likelihood of achieving comparable response with either a JAK inhibitor or a Th2-targeted therapy, thus supporting treatment choice based on other factors such as safety, comorbidities, and patient preference.

The AdvanceAD-Tx test is intended to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis.

Castle Biosciences, Inc. | Sherri Borman, PhD, HCLD, Lab Director

About the Test

The AdvanceAD-Tx test is a molecular profile test intended to be used by the treating clinician for adolescents and adults (≥12 years) diagnosed with moderate-to-severe atopic dermatitis (AD) who are considering starting or changing systemic therapy.

The AdvanceAD-Tx test has been clinically validated to identify patients with AD who have a JAK Inhibitor Responder Profile and achieve significantly more effective and rapid responses to JAK inhibitor therapy on the starting dose than Th2-targeted therapies by 3 months. The test also identified patients with a Th2 Molecular Profile for whom therapy responses by 3 months were not statistically different for patients treated with Th2-targeted therapies compared to JAK inhibitor therapies. The AdvanceAD-Tx test is intended to provide a framework that guides individualized systemic treatment selection and improved outcomes for patients with AD.

The test uses a non-invasive lesional skin scraping; epidermal surface sample. The collected specimen undergoes RNA isolation and transcriptomic profiling to generate a clinically actionable result. AdvanceAD-Tx analyzes RNA expression across a 487-gene panel encompassing 12 cutaneous and inflammatory pathways.

AdvanceAD-Tx results are intended to aid, not replace, clinical judgment. All treatment decisions should be made by the clinician in the context of the patient's overall clinical status.

Silverberg J, et al., Fall Clinical Dermatology Conference, 2025. Data on file.

Castle Biosciences, Inc. | Sherri Borman, PhD, HCLD, Lab Director

REJECTED SPECIMEN NOTIFICATION

Patient:
Sex:
DOB:
Client:
Provider:

Specimen ID:
Sample location:
Collected:
Received:
Reported:

Reason for Rejection

Insufficient quality/quantity of RNA

About the Test

The AdvanceAD-Tx test is a molecular profile test intended to be used by the treating clinician for adolescents and adults (≥12 years) diagnosed with moderate-to-severe atopic dermatitis (AD) who are considering starting or changing systemic therapy.

The AdvanceAD-Tx test has been clinically validated to identify patients with AD who have a JAK Inhibitor Responder Profile and achieve significantly more effective and rapid responses to JAK inhibitor therapy on the starting dose than Th2-targeted therapies by 3 months. The test also identified patients with a Th2 Molecular Profile for whom therapy responses by 3 months were not statistically different for patients treated with Th2-targeted therapies compared to JAK inhibitor therapies. The AdvanceAD-Tx test is intended to provide a framework that guides individualized systemic treatment selection and improved outcomes for patients with AD.

The test uses a non-invasive lesional skin scraping; epidermal surface sample. The collected specimen undergoes RNA isolation and transcriptomic profiling to generate a clinically actionable result. AdvanceAD-Tx analyzes RNA expression across a 487-gene panel encompassing 12 cutaneous and inflammatory pathways.

Castle Biosciences, Inc. | Sherri Borman, PhD, HCLD, Lab Director

FINAL REPORT: UNABLE TO SEQUENCE

Patient:
Sex:
DOB:
Client:
Provider:

Specimen ID:
Sample location:
Collected:
Received:
Reported:

Reason for Rejection

Insufficient RNA for Testing

About the Test

The AdvanceAD-Tx test is a molecular profile test intended to be used by the treating clinician for adolescents and adults (≥12 years) diagnosed with moderate-to-severe atopic dermatitis (AD) who are considering starting or changing systemic therapy.

The AdvanceAD-Tx test has been clinically validated to identify patients with AD who have a JAK Inhibitor Responder Profile and achieve significantly more effective and rapid responses to JAK inhibitor therapy on the starting dose than Th2-targeted therapies by 3 months. The test also identified patients with a Th2 Molecular Profile for whom therapy responses by 3 months were not statistically different for patients treated with Th2-targeted therapies compared to JAK inhibitor therapies. The AdvanceAD-Tx test is intended to provide a framework that guides individualized systemic treatment selection and improved outcomes for patients with AD.

The test uses a non-invasive lesional skin scraping; epidermal surface sample. The collected specimen undergoes RNA isolation and transcriptomic profiling to generate a clinically actionable result. AdvanceAD-Tx analyzes RNA expression across a 487-gene panel encompassing 12 cutaneous and inflammatory pathways.

Castle Biosciences, Inc. | Sherri Borman, PhD, HCLD, Lab Director